This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Raises Concerns About Cell Therapeutics' Cancer Drug

(Updated with stock price)

WASHINGTON ( TheStreet) -- Drug reviewers working for the Food and Drug Administration raised concerns about the efficacy and safety of Cell Therapeutics' (CTIC - Get Report) lymphoma drug pixantrone drug, according to a review of the drug posted to the agency's Web site Monday.

Shares of Cell Therapeutics fell 30% to 73 cents a share in early Monday trading.

Cell Therapeutics only enrolled 140 out of a planned 320 patients with aggressive, non-Hodgkin's lymphoma in its pivotal phase III study of pixantrone. As a result, the FDA raises doubts about "the level of evidence necessary to draw conclusions from this Phase 3 study and the reliability of these conclusions," according to the agency's review.

The agency is also concerned about "substantial hematologic and cardiac toxicity" related to treatment with pixantrone.

Cell Therapeutics's decision to halt enrollment early in the pixantrone study and analyze the data earlier than expected invalidated the Special Protocol Assessment (SPA) the company had with the FDA for the conduct of the study, according to the FDA's review.

The small number of patients in the pixantrone phase III study, concerns over the heart safety of the drug and the lack of an SPA were all issues expected to be troublesome for Cell Therapeutics.

The FDA is convening an advisory panel meeting on Feb. 10 to review pixantrone. Cell Therapeutics is trying to get the drug approved as a treatment for patients with advanced, aggressive non-Hodgkin's lymphoma.

Cancer experts on the FDA's Oncologic Drugs Advisory Committee (ODAC) will be reviewing data from a phase III study of pixantrone known as "EXTEND" and voting on whether or not to recommend the drug's approval by the agency.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CTIC $1.96 -0.76%
AAPL $125.56 -0.70%
FB $86.93 -0.41%
GOOG $522.27 -0.22%
TSLA $278.58 -0.51%

Markets

DOW 17,633.43 -96.68 -0.55%
S&P 500 2,061.31 -15.47 -0.74%
NASDAQ 4,969.1880 -40.0260 -0.80%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs